ADVERTIMA
28.7.2020 09:02:08 CEST | Business Wire | Press release
Advertima , an emerging computer vision platform provider, today announces the close of a €15 million Series A investment round led by existing shareholder Swiss real estate company, Fortimo Group. Advertima empowers grocers and other retailers to create smart spaces that offer consumer-centric, frictionless and relevant in-store shopping experiences. The investment will enable the start-up to further develop their platform on a global scale and strengthen their position as a critical player in the wider ecosystem of the smart space environments.
Through computer vision, machine learning and artificial intelligence (AI), Advertima has created the ‘Human Data Layer’, which visually interprets human behaviour in physical spaces. By providing a real-time and easily accessible data stream, Advertima gives the ability for the smart spaces of the future to interact with people in a seamless and meaningful way.
The first sector that Advertima has set its sights on is grocery retail. In a fast-changing retail world that is quickly adapting to the impact of COVID-19, Advertima’s technology helps fast-track the evolution of grocery retailers. Advertima offers smart inventory management and autonomous checkout while also providing engaging and relevant content on smart digital screens throughout the in-store shopping journey of every customer. By making retail spaces smart, grocers maximise the efficiency of their stores, increase their revenues and generate greater returns per square meter.
In the near future, smart spaces will be ubiquitous and a part of the fabric of everyday life. Advertima plays a crucial role in the emerging smart retail ecosystem, powered by their Human Data Layer. Consumers are at the core of the evolution of smart spaces and will expect a living and working environment where interaction with technology is seamless and unnoticeable.
Advertima’s smart retail portfolio has been developed with Switzerland’s largest retailer, Migros and the international grocer SPAR. The technology is already being used by 14 companies across eight different countries.
“It is clear that the rapid digitalisation of our society is going to have an impact on consumer habits, especially in the retail sector,” says Fortimo Group Founder Remo Bienz. “ Advertima is at the cutting-edge of technology in the retail space. As a long-standing shareholder, we know how visionary their technology is, but also how it has been successfully adopted by major, global organisations and already generated significant revenues. We’re excited to be part of Advertima’s journey.”
“We’ll be investing €25 million in the further development of our smart retail solutions over the next two years. €10 million of this investment will be financed by our own revenues so this €15 million round is a crucial milestone to help us achieve our vision for how the world will look by 2030,” says Advertima Co-Founder and CEO Iman Nahvi. “We see a world where the physical and digital layers are merged to enhance our daily professional and private lives. Advertima’s Human Data Layer will be one of the irreplaceable components in this whole ecosystem of applications and technologies that will build the foundation of our future lives.”
“Since its founding in 2016, our Swiss start-up has had a global technology vision. This funding round brings our vision nearer to reality,” says Damir Bogdan, Advertima Seed Investor and President of the Board.
For more information read Advertima CEO’s blog post here: https://advertima.com/blog/detail/series-a-ceo-message/
-ENDS -
Notes to Editors:
About Advertima
Advertima is a 3D computer vision platform provider founded in 2016 and headquartered in St.Gallen, Switzerland. Advertima visually interprets human behaviour in the physical world, enabling smart spaces of the future to interact with people in seamless and meaningful ways. Their real-time and easily accessible data stream, called the ‘Human Data Layer’, powers their smart retail solutions, including Autonomous Store and Smart Signage. These next-generation solutions empower companies to create the customer experience of tomorrow: frictionless, relevant and highly-targeted. Advertima is fully compliant with the EU General Data Privacy Regulation (GDPR).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200728005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom